BlockMedx (MDX) WEB2 Rating, Reviews and Details

Sale

Jul, 2018

Sep, 2018

100% completed

Raised funds - no Data

past

Token Details

Accepted Currencies

ETH, BTC, WAN

Company Details

Registered Country

United States

Additional Details

KYC

Yes

About BlockMedx (MDX)

A closed-end, cryptographically secure solution for transmitting prescriptions using the Ethereum blockchain

BlockMedx restores complete control of prescriptive authority to prescribers. No more prescription forgeries, duplicates, or over-prescribing

Each prescription must be paired to a native MDX token which ensures the security of the network. Patients will also use MDX tokens to pay their co-pays at their pharmacy and doctor's office.

Features

A closed-end, cryptographically secure solution for transmitting prescriptions using the Ethereum blockchain

BlockMedx restores complete control of prescriptive authority to prescribers. No more prescription forgeries, duplicates, or over-prescribing

Each prescription must be paired to a native MDX token which ensures the security of the network. Patients will also use MDX tokens to pay their co-pays at their pharmacy and doctor's office.

Technical Info

Ethereum ERC20 standard token.

BlockMedx (MDX) Roadmap

Q1 2017

The idea of BlockMedax is born;
Start of conceptual work.

Q2 2017

Development of basic prototype;
Outreach to relevant stakeholders and discussion of proposed solution.

Q3 2017

Completion of MVP;
BlockMedx network goes live.

Q2 2018

Private sale;
MassChallenge Accelerator start.

Q3 2018

Public token sale;
Intensive outreach to strategic partners.

Q4 2018

Pilot projects online: targeted areas will be Texas, Kentucky, Ohio and West Virginia;
Version 2 Application Upgrades as Protocol Advances.

Q1 2019

Intensify implementations with healthcare systems;
Rapid scalling into additional states with the highest opioid death rates;
EMR and Telehealth platform API Access and Integration.

Q2 2019

Key partnership with addiction treatment organizations for patient education, communication, and early intervention;
Expansion pf network into all prescription drugs with incorporation of communication, education, and early intervention incentive structures.

Q3 2019

Partnerships with payors and healthcare systems to allow discounted payments through patient portal and introduce new value based incentive structure that promotes early prevention rather than treatment.

Q4 2019

ML/AI implementations to automate detection of fraud and abuse in the healthcare system - important to prevent patients from being lost in the system after it is too late;
Integration with Pharmaceutical supply chain to prevent counterfeit drugs from entering the market.